Integrative clustering of multi-omics data revealed 2 subgroups of patients with metastatic-like biology that have distinct biology. 17% of the patients show greater genomic instability and present with targetable immune biology –that can be identified with the combination of the DDRD and PCM assays. This subgroup can be reproduced with the expression of 8q genes alone. The group is also identified in an independent data set and represents 14% of the n=321 cohort. The Metastatic-like DDRD group is shown to be at increased risk of biochemical recurrence & metastatic disease. It may represent a viable target population for immune checkpoint and DNA damaging treatment.